title: Azilsartan medoxomil (Edarbi) the eighth ARB.
abstract: The angiotensin receptor blocker (ARB) azilsartan medoxomil (Edarbi-Takeda) was recently approved by the FDA for oral treatment of hypertension, either alone or combined with other drugs. It is the eighth ARB approved for this indication.
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D010069:Oxadiazoles / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D044140:Receptor, Angiotensin, Type 1 / Q000502:physiology
chemical_list: D057911:Angiotensin Receptor Antagonists; D001562:Benzimidazoles; D010069:Oxadiazoles; D044140:Receptor, Angiotensin, Type 1; C557413:azilsartan medoxomil